The company's fair value estimate was raised to $104.27, driven by an improved growth outlook. Wells Fargo upgraded the stock, citing increased confidence in its drug pipeline and progress in regulatory approvals for new oncology and HIV treatments. Analysts see pipeline advancements and diversified business development as easing concerns over a key drug's eventual patent loss. BofA raised its price target to $105, maintaining a Buy rating. However, the company faces headwinds from softening demand for its Gardasil vaccine in China and Japan, putting pressure on its vaccine portfolio.